Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia.
Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A. Dallmann R, et al. Among authors: feurer a. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):163-174. doi: 10.1007/s13539-011-0039-1. Epub 2011 Aug 28. J Cachexia Sarcopenia Muscle. 2011. PMID: 21966642 Free PMC article.
From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.
Nordhoff S, López-Canet M, Hoffmann-Enger B, Bulat S, Cerezo-Gálvez S, Hill O, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. Nordhoff S, et al. Among authors: feurer a. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4818-23. doi: 10.1016/j.bmcl.2009.06.036. Epub 2009 Jun 13. Bioorg Med Chem Lett. 2009. PMID: 19576767
Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.
Nordhoff S, Cerezo-Gálvez S, Deppe H, Hill O, López-Canet M, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. Nordhoff S, et al. Among authors: feurer a. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4201-3. doi: 10.1016/j.bmcl.2009.05.109. Epub 2009 May 30. Bioorg Med Chem Lett. 2009. PMID: 19515557
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, Gerisch M, Kern A, Knorr A, Lang D, Muenter K, Radtke M, Schirok H, Schlemmer KH, Stahl E, Straub A, Wunder F, Stasch JP. Mittendorf J, et al. Among authors: feurer a. ChemMedChem. 2009 May;4(5):853-65. doi: 10.1002/cmdc.200900014. ChemMedChem. 2009. PMID: 19263460 Free article.
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
Schirok H, Kast R, Figueroa-Pérez S, Bennabi S, Gnoth MJ, Feurer A, Heckroth H, Thutewohl M, Paulsen H, Knorr A, Hütter J, Lobell M, Münter K, Geiss V, Ehmke H, Lang D, Radtke M, Mittendorf J, Stasch JP. Schirok H, et al. Among authors: feurer a. ChemMedChem. 2008 Dec;3(12):1893-904. doi: 10.1002/cmdc.200800211. ChemMedChem. 2008. PMID: 18973168
15 results